Kamyar Kalantar-Zadeh M.D. to Chelating Agents
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Chelating Agents.
Connection Strength
1.741
-
Novel approaches to management of hyperkalaemia in kidney transplantation. Curr Opin Nephrol Hypertens. 2021 01; 30(1):27-37.
Score: 0.706
-
Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):519-30.
Score: 0.331
-
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis. J Ren Nutr. 2019 09; 29(5):428-437.
Score: 0.154
-
Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes. Am J Nephrol. 2017; 45(5):431-441.
Score: 0.137
-
Management of natural and added dietary phosphorus burden in kidney disease. Semin Nephrol. 2013 Mar; 33(2):180-90.
Score: 0.102
-
Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol. 2010 Jul; 74(1):12-8.
Score: 0.085
-
Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am J Nephrol. 2010; 31(5):419-25.
Score: 0.084
-
Battleground: chronic kidney disorders mineral and bone disease--calcium obsession, vitamin d, and binder confusion. Clin J Am Soc Nephrol. 2008 Jan; 3(1):168-73.
Score: 0.071
-
Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008; 28(2):275-9.
Score: 0.071